SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001213900-21-035567
Filing Date
2021-07-02
Accepted
2021-07-02 16:15:52
Documents
4
Group Members
APTA FINANCE SAAPTAFIN S.P.A.ENRICO CAVAZZAFRANCESCA CAVAZZAMARTINA CAVAZZA PRETAPAOLO CAVAZZASILVIA CAVAZZA

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 25 TO SCHEDULE 13D ea143641-13da25esset_regen.htm SC 13D/A 206565
2 JOINT FILING AGREEMENT. ea143641ex-1_essetifin.htm EX-1 31866
3 SECURITIES PURCHASE AGREEMENT, DATED AS OF JUNE 28, 2021, BY AND BETWEEN THE ISS ea143641ex-2_essetifin.htm EX-2 238671
4 FORM OF 2021 WARRANT ea143641ex-3_essetifin.htm EX-3 116288
  Complete submission text file 0001213900-21-035567.txt   595197
Mailing Address 15245 SHADY GROVE ROAD SUITE 470 ROCKVILLE MD 20850
Business Address 15245 SHADY GROVE ROAD SUITE 470 ROCKVILLE MD 20850 301-208-9191
REGENERX BIOPHARMACEUTICALS INC (Subject) CIK: 0000707511 (see all company filings)

IRS No.: 521253406 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-37889 | Film No.: 211070256
SIC: 2834 Pharmaceutical Preparations

Mailing Address VIA SUDAFRICA 20 ROME L6 00144
Business Address
Essetifin SPA (Filed by) CIK: 0001092601 (see all company filings)

Fiscal Year End: 1231
Type: SC 13D/A